Top

Pediatric Rheumatology

Published in:

Open Access 01-12-2020 | Juvenile Rheumatoid Arthritis | Research article

Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA

Authors: Justyna Roszkiewicz, Zbigniew Swacha, Elżbieta Smolewska

Published in: Pediatric Rheumatology | Issue 1/2020

Abstract

Background

Methotrexate is the most commonly used disease-modifying antirheumatic drug recommended in the treatment of juvenile idiopathic arthritis. It can be administered orally or subcutaneously, the latter method is associated with fewer side effects and higher drug bioavailability. Nevertheless, the pain associated with injection is a considerable drawback of this treatment option in the pediatric population. Currently, there are two single-use subcutaneous injection devices available: the prefilled syringe and the prefilled pen. This prospective, two-sequence crossover study aimed to compare ease of use, frequency of therapy side effects, injection-site pain and parent/patient preference of those methotrexate parenteral delivery systems.

Methods

Twenty-three patients with juvenile idiopathic arthritis, already treated with subcutaneous methotrexate in the form of prefilled syringe in the period October 2018 – April 2019 completed a questionnaire evaluating their experience with this device. Subsequently, children received a one-month supply of pen autoinjector and completed the same questionnaire, regarding their experience with the new methotrexate delivery system. If the patient was not performing the injections himself the questionnaires were completed by the caregiver administrating MTX. The results obtained in both questionnaires were compared using the Wilcoxon matched-pairs signed-rank test.

Results

82,6% patients and their caregivers voted for the prefilled pen as their preferred method of subcutaneous methotrexate administration. Moreover, the injection with the prefilled pen was reported as less painful in comparison to the prefilled syringe (p < 0.01). Side effects of methotrexate were less pronounced after the prefilled pen treatment, this difference was most prominent regarding gastrointestinal adverse events associated with the injection (p < 0.01).

Conclusion

Administration of methotrexate using the pen device is a promising way of subcutaneous methotrexate delivery in children with juvenile idiopathic arthritis, as the injection is less painful and associated with fewer side effects.

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet (London, England). 2007;369(9563):767–78. https://doi.org/10.1016/S0140-6736(07)60363-8.CrossRef

Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.PubMed

Roszkiewicz J, Smolewska E. In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis—Are We Getting Closer to Personalised Medicine? Curr Rheumatol Rep. 2017;19(4). https://doi.org/10.1007/s11926-017-0646-8.

Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: Advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol. 2018;16(1). https://doi.org/10.1186/s12969-018-0255-8.

Blazina Š, Markelj G, Avramovič MZ, Toplak N, Avčin T. Management of Juvenile Idiopathic Arthritis: a clinical guide. Pediatr Drugs. 2016;18(6):397–412. https://doi.org/10.1007/s40272-016-0186-0.CrossRef

Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20(11):1845–9.PubMed

Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81. https://doi.org/10.1002/art.23144.CrossRefPubMed

Yadlapati S, Efthimiou P. Inadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics? Rheumatol Int. 2016;36(5):627–33. https://doi.org/10.1007/s00296-016-3447-x.CrossRefPubMed

Guimbal-Schmolck C, Demary W, Schwenke H, et al. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. Patient Prefer Adherence. 2014;8:1061. https://doi.org/10.2147/PPA.S64111.CrossRefPubMedPubMedCentral

10.

Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The faces pain scale-revised: toward a common metric in pediatric pain measurement. Pain. 2001;93(2):173–83. https://doi.org/10.1016/s0304-3959(01)00314-1.CrossRefPubMed

11.

Babl FE, Crellin D, Cheng J, Sullivan TP, O’Sullivan R, Hutchinson A. The use of the faces, legs, activity, cry and Consolability scale to assess procedural pain and distress in young children. Pediatr Emerg Care. 2012;28(12):1281–96. https://doi.org/10.1097/PEC.0b013e3182767d66.CrossRefPubMed

12.

Flacc Pain Scale | Medical Calculators | Pediatric Oncall. https://www.pediatriconcall.com/calculators/flacc-pain-scale-calculator. Accessed August 31, 2019.

13.

Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology. 2006;45(12):1575–6. https://doi.org/10.1093/rheumatology/kel369.CrossRefPubMed

14.

Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–44.CrossRefPubMedPubMedCentral

15.

Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the Sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2018;5(1):231–42. https://doi.org/10.1007/s40744-017-0090-2.CrossRefPubMed

16.

Borrás-Blasco J, Gracia-Pérez A, Rosique-Robles JD, Casterá MD-E, Abad FJ. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10(3):301–7. https://doi.org/10.1517/14712590903530633.CrossRefPubMed

17.

Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-Administration of the Fully Human, monoclonal antibody Adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619–29. https://doi.org/10.1016/j.clinthera.2006.10.006.CrossRefPubMed

18.

Hsiao B, Fraenkel L. Patient preferences for rheumatoid arthritis treatment. Curr Opin Rheumatol. 2019;31(3):256–63. https://doi.org/10.1097/BOR.0000000000000591.CrossRefPubMedPubMedCentral

19.

Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysis. Semin Arthritis Rheum. 2016;45(6):656–62. https://doi.org/10.1016/j.semarthrit.2015.11.004.CrossRefPubMed

20.

Pichlmeier U, Heuer K-U. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014;32(4):563–71.PubMed

21.

Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the self-injection assessment questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(1):2. https://doi.org/10.1186/1477-7525-9-2.CrossRefPubMedPubMedCentral

22.

Shin D, Lee Y, Jeong D, Ellis-Pegler R. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. Drug Des Devel Ther. 2018;12:3799–805. https://doi.org/10.2147/DDDT.S169082.CrossRefPubMedPubMedCentral

23.

van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2007;25(3):480–5.PubMed

Title: Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA
Authors: Justyna Roszkiewicz
Zbigniew Swacha
Elżbieta Smolewska
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Juvenile Rheumatoid Arthritis
Methotrexate
Methotrexate
Juvenile Rheumatoid Arthritis
Published in: Pediatric Rheumatology / Issue 1/2020
Electronic ISSN: 1546-0096
DOI: https://doi.org/10.1186/s12969-020-00455-4

At a glance: The STEP trials

Springer Medicine

Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Adenosine deaminase 2 activity negatively correlates with age during childhood

Usefulness of magnetic resonance enterography in detecting signs of sacroiliitis in young patients with inflammatory bowel disease

Onset age is a risk factor for refractory pediatric IgA vasculitis: a retrospective cohort study

Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study

Joint injection practice variations in pediatric rheumatology – a global survey and call for action

A case of rectal ulcers during aspirin therapy in acute Kawasaki disease